HRS-9231 clinical trials
Also written HRS-9231.
How each study uses HRS-9231 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-9231 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2024 | 3 |
| 2025 | 2 |
Who runs them
Industry 5 · Other 0
Shanghai Shengdi Pharmaceutical Co., Ltd (4) · Jiangsu HengRui Medicine Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses HRS-9231 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord ConditionsNot yet recruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT06731829Written as HRS-9231
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) LesionsCompletedPhase 3Shanghai Shengdi Pharmaceutical Co., LtdNCT07275723Written as HRS-9231 Injection
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) LesionsCompletedPhase 3Shanghai Shengdi Pharmaceutical Co., LtdNCT07275814Written as HRS-9231 Injection
- Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy SubjectsCompletedPhase 1Shanghai Shengdi Pharmaceutical Co., LtdNCT07123376Written as HRS-9231
- Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal FunctionCompletedPhase 1Shanghai Shengdi Pharmaceutical Co., LtdNCT06657560Written as HRS-9231